Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

clopidogrel, Acetylsalicylic acid

Available from:

Sanofi-Aventis Groupe

ATC code:

B01AC30

INN (International Name):

clopidogrel, acetylsalicylic acid

Therapeutic group:

Antitrombotična sredstva

Therapeutic area:

Acute Coronary Syndrome; Myocardial Infarction

Therapeutic indications:

Akutni Koronarni SyndromeMyocardial Infarkt.

Product summary:

Revision: 22

Authorization status:

Pooblaščeni

Authorization date:

2010-03-14

Patient Information leaflet

                                30
Shranjujte pri temperaturi do 25

C.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
Upoštevajte lokalne zahteve za odlaganje.
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
sanofi-aventis groupe
54, rue La Boétie
F-75008 Paris
Francija
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/10/623/001 14 filmsko obloženih tablet
EU/1/10/623/002 28 filmsko obloženih tablet
EU/1/10/623/003 30 x 1 filmsko obloženih tablet
EU/1/10/623/004 50 x 1 filmsko obloženih tablet
EU/1/10/623/005 84 filmsko obloženih tablet
EU/1/10/623/006 90 x 1 filmsko obloženih tablet
EU/1/10/623/007 100 x 1 filmsko obloženih tablet
EU/1/10/623/015 30 filmsko obloženih tablet
13.
ŠTEVILKA SERIJE
Serija:
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/75 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
31
PC:
SN:
NN:
32
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU
PRETISNI OMOT / 14, 28 IN 84 TABLET
1.
IME ZDRAVILA
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/75 mg tablete
klopidogrel/acetilsalicilna kislina
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
sanofi-aventis groupe
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Serija:
5.
DRUGI PODATKI
Pon
Tor
Sre
Čet
Pet
Sob
Ned
33
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU
PRETISNI OMOT / 30, 30X1, 50X1, 90X1 ALI 100X1 TABLET
1.
IME ZDRAVILA
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/75 mg tablete
klopidogrel/acetilsalicilna kislina
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
sanofi-aventis groupe
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Serija:
5.
DRUGI PODATKI
34
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA
1.
IME ZDRAVILA
Klopidogrel/acetilsalicilna kisl
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
1B
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/75 mg filmsko
obložene tablete
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/100 mg filmsko
obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/75 mg filmsko
obložene tablete
Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (kot
hidrogensulfata) in 75 mg acetilsalicilne
kisline (ASA).
_Pomožne snovi z znanim učinkom: _
Ena filmsko obložena tableta vsebuje 7 mg laktoze in 3,3 mg
hidrogeniranega ricinusovega olja.
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/100 mg filmsko
obložene tablete
Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (kot
hidrogensulfata) in 100 mg
acetilsalicilne kisline (ASA).
_Pomožne snovi z znanim učinkom: _
Ena filmsko obložena tableta vsebuje 8 mg laktoze in 3,3 mg
hidrogeniranega ricinusovega olja.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta (tableta)
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/75 mg filmsko
obložene tablete
Rumena, ovalna, rahlo bikonveksna, z vtisnjeno oznako "C75" na eni
strani in "A75" na drugi strani.
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/100 mg filmsko
obložene tablete
Svetlo rožnata, ovalna, rahlo bikonveksna, z vtisnjeno oznako "C75"
na eni strani in "A100" na drugi
strani.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Klopidogrel/acetilsalicilna kislina Zentiva je indiciran za
sekundarno preprečevanje
aterotrombotičnih dogodkov pri odraslih bolnikih, ki že jemljejo
klopidogrel in acetilsalicilno kislino
(ASA). Klopidogrel/acetilsalicilna kislina Zentiva je kombinirano
zdravilo s stalnim odmerkom za
nadaljevalno zdravljenje pri:
-
akutnem koronarnem sindromu brez elevacije ST spojnice (nestabilna
angina ali miokardni
infarkt brez Q zobca), vključno z bolniki, katerim je bila vstavljena
opornica po perkutani
koronarni intervenciji,
-
akutnem miokardnem infarktu z 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 13-11-2019
Summary of Product characteristics Summary of Product characteristics Bulgarian 13-11-2019
Public Assessment Report Public Assessment Report Bulgarian 14-04-2016
Patient Information leaflet Patient Information leaflet Spanish 13-11-2019
Public Assessment Report Public Assessment Report Spanish 14-04-2016
Patient Information leaflet Patient Information leaflet Czech 13-11-2019
Public Assessment Report Public Assessment Report Czech 14-04-2016
Patient Information leaflet Patient Information leaflet Danish 13-11-2019
Public Assessment Report Public Assessment Report Danish 14-04-2016
Patient Information leaflet Patient Information leaflet German 13-11-2019
Public Assessment Report Public Assessment Report German 14-04-2016
Patient Information leaflet Patient Information leaflet Estonian 13-11-2019
Public Assessment Report Public Assessment Report Estonian 14-04-2016
Patient Information leaflet Patient Information leaflet Greek 13-11-2019
Public Assessment Report Public Assessment Report Greek 14-04-2016
Patient Information leaflet Patient Information leaflet English 13-11-2019
Public Assessment Report Public Assessment Report English 14-04-2016
Patient Information leaflet Patient Information leaflet French 13-11-2019
Public Assessment Report Public Assessment Report French 14-04-2016
Patient Information leaflet Patient Information leaflet Italian 13-11-2019
Public Assessment Report Public Assessment Report Italian 14-04-2016
Patient Information leaflet Patient Information leaflet Latvian 13-11-2019
Public Assessment Report Public Assessment Report Latvian 14-04-2016
Patient Information leaflet Patient Information leaflet Lithuanian 13-11-2019
Summary of Product characteristics Summary of Product characteristics Lithuanian 13-11-2019
Public Assessment Report Public Assessment Report Lithuanian 14-04-2016
Patient Information leaflet Patient Information leaflet Hungarian 13-11-2019
Summary of Product characteristics Summary of Product characteristics Hungarian 13-11-2019
Public Assessment Report Public Assessment Report Hungarian 14-04-2016
Patient Information leaflet Patient Information leaflet Maltese 13-11-2019
Public Assessment Report Public Assessment Report Maltese 14-04-2016
Patient Information leaflet Patient Information leaflet Dutch 13-11-2019
Public Assessment Report Public Assessment Report Dutch 14-04-2016
Patient Information leaflet Patient Information leaflet Polish 13-11-2019
Public Assessment Report Public Assessment Report Polish 14-04-2016
Patient Information leaflet Patient Information leaflet Portuguese 13-11-2019
Summary of Product characteristics Summary of Product characteristics Portuguese 13-11-2019
Public Assessment Report Public Assessment Report Portuguese 14-04-2016
Patient Information leaflet Patient Information leaflet Romanian 13-11-2019
Public Assessment Report Public Assessment Report Romanian 14-04-2016
Patient Information leaflet Patient Information leaflet Slovak 13-11-2019
Public Assessment Report Public Assessment Report Slovak 14-04-2016
Patient Information leaflet Patient Information leaflet Finnish 13-11-2019
Public Assessment Report Public Assessment Report Finnish 14-04-2016
Patient Information leaflet Patient Information leaflet Swedish 13-11-2019
Public Assessment Report Public Assessment Report Swedish 14-04-2016
Patient Information leaflet Patient Information leaflet Norwegian 13-11-2019
Summary of Product characteristics Summary of Product characteristics Norwegian 13-11-2019
Patient Information leaflet Patient Information leaflet Icelandic 13-11-2019
Summary of Product characteristics Summary of Product characteristics Icelandic 13-11-2019
Patient Information leaflet Patient Information leaflet Croatian 13-11-2019
Public Assessment Report Public Assessment Report Croatian 14-04-2016